Find Orforglipron Calcium Hydrate manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

0

JDMF

0

EU WC

0

KDMF

0

VMF

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

Europe

0

Canada

0

Australia

0

South Africa

0

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Regulatory FDF Prices

NA

MARKET PLACE

0

FDF

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 2212020-52-3, Ly3502970, Chembl4446782, Ly-3502970, 3-[(1s,2s)-1-[5-[(4s)-2,2-dimethyloxan-4-yl]-2-[(4s)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4h-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methylcyclopropyl]-4h-1,2,4-oxadiazol-5-one, 3-[(1s,2s)-1-(5-[(4s)-2,2-dimethyloxan-4-yl]-2-{(4s)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1h-indazol-5-yl)-2-oxo-2,3-dihydro-1h-imidazol-1-yl]-4-methyl-2,4,6,7-tetrahydro-5h-pyrazolo[4,3-c]pyridine-5-carbonyl}-1h-indol-1-yl)-2-methylcyclopropyl]-1,2,4-oxadiazol-5(4h)-one
Molecular Formula
C48H48F2N10O5
Molecular Weight
883.0  g/mol
InChI Key
USUWIEBBBWHKNI-KHIFEHGGSA-N
FDA UNII
7ZW40D021M

Orforglipron Calcium Hydrate
1 2D Structure

Orforglipron Calcium Hydrate

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
3-[(1S,2S)-1-[5-[(4S)-2,2-dimethyloxan-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methylcyclopropyl]-4H-1,2,4-oxadiazol-5-one
2.1.2 InChI
InChI=1S/C48H48F2N10O5/c1-25-18-32(19-26(2)40(25)49)60-42(58-16-15-57(46(58)63)37-11-10-36-33(41(37)50)24-51-55(36)7)39-28(4)56(14-12-34(39)53-60)43(61)38-21-31-20-29(30-13-17-64-47(5,6)23-30)8-9-35(31)59(38)48(22-27(48)3)44-52-45(62)65-54-44/h8-11,15-16,18-21,24,27-28,30H,12-14,17,22-23H2,1-7H3,(H,52,54,62)/t27-,28-,30-,48-/m0/s1
2.1.3 InChI Key
USUWIEBBBWHKNI-KHIFEHGGSA-N
2.1.4 Canonical SMILES
CC1CC1(C2=NOC(=O)N2)N3C4=C(C=C(C=C4)C5CCOC(C5)(C)C)C=C3C(=O)N6CCC7=NN(C(=C7C6C)N8C=CN(C8=O)C9=C(C1=C(C=C9)N(N=C1)C)F)C1=CC(=C(C(=C1)C)F)C
2.1.5 Isomeric SMILES
C[C@H]1C[C@]1(C2=NOC(=O)N2)N3C4=C(C=C(C=C4)[C@H]5CCOC(C5)(C)C)C=C3C(=O)N6CCC7=NN(C(=C7[C@@H]6C)N8C=CN(C8=O)C9=C(C1=C(C=C9)N(N=C1)C)F)C1=CC(=C(C(=C1)C)F)C
2.2 Other Identifiers
2.2.1 UNII
7ZW40D021M
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Ly3502970

2.3.2 Depositor-Supplied Synonyms

1. 2212020-52-3

2. Ly3502970

3. Chembl4446782

4. Ly-3502970

5. 3-[(1s,2s)-1-[5-[(4s)-2,2-dimethyloxan-4-yl]-2-[(4s)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4h-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methylcyclopropyl]-4h-1,2,4-oxadiazol-5-one

6. 3-[(1s,2s)-1-(5-[(4s)-2,2-dimethyloxan-4-yl]-2-{(4s)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1h-indazol-5-yl)-2-oxo-2,3-dihydro-1h-imidazol-1-yl]-4-methyl-2,4,6,7-tetrahydro-5h-pyrazolo[4,3-c]pyridine-5-carbonyl}-1h-indol-1-yl)-2-methylcyclopropyl]-1,2,4-oxadiazol-5(4h)-one

7. V6g

8. Orforglipron [inn]

9. Orforglipron [usan]

10. Ly3502970 (orforglipron)

11. Owl833

12. Schembl21175277

13. Gtpl12175

14. 7zw40d021m

15. Ex-a7751

16. Bdbm50514045

17. Akos040733262

18. Glp-1 Receptor Agonist 1;orforglipron

19. Ms-31635

20. Hy-112185

21. Cs-0043632

22. 1,2,4-oxadiazol-5(2h)-one, 3-[(1s,2s)-1-[2-[[(4s)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1h-indazol-5-yl)-2,3-dihydro-2-oxo-1h-imidazol-1-yl]-2,4,6,7-tetrahydro-4-methyl-5h-pyrazolo[4,3-c]pyridin-5-yl]carbonyl]-5-[(4s)-tetrahydro-2,2-dimethyl-2h-pyran-4-yl]-1h-indol-1-yl]-2-methylcyclopropyl]-

23. 3-[(1s,2s)-1-({2-(4-fluoro-3,5-dimethylphenyl)-3-({3-[3-(4-fluoro-1-methyl-1h-indazol-5-yl)-2-oxo-2,3-dihydro-1h-imidazol-1-yl]-4-methyl-2,4,6,7-tetrahydro-5h-pyrazolo[4,3-c]pyridin-5-yl}carbonyl)-5-[(4s)-2,2-dimethyloxan-4-yl]-1h-indol-1-yl}-2-methylcyclopropyl]-5-oxo-1,2,4-oxadiazol-4(5h)-ide

2.4 Create Date
2019-01-28
3 Chemical and Physical Properties
Molecular Weight 883.0 g/mol
Molecular Formula C48H48F2N10O5
XLogP36.8
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count10
Rotatable Bond Count7
Exact Mass g/mol
Monoisotopic Mass g/mol
Topological Polar Surface Area144
Heavy Atom Count65
Formal Charge0
Complexity1950
Isotope Atom Count0
Defined Atom Stereocenter Count4
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

USDMF

read-more
read-moreread-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothFujian Genohope Biotech is a leading provider of high-potency peptide APIs, offering GMP quality and worldwide delivery.

Flag China
Digital Content Digital Content

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 42393

Submission : 2025-09-16

Status : Active

Type : II

Company Banner

02

PEGS Boston Summit
Not Confirmed

03

PEGS Boston Summit
Not Confirmed

04

PEGS Boston Summit
Not Confirmed

04

PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 41815

Submission : 2025-04-27

Status : Active

Type : II

blank

05

El-peptido (shanghai) Biopharmaceuti...

Country

USDMF

arrow
PEGS Boston Summit
Not Confirmed

05

El-peptido (shanghai) Biopharmaceuti...

Country
arrow
PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 43446

Submission : 2026-01-05

Status : Active

Type : II

blank

06

Ningxia Labschem Co Ltd

Country

USDMF

arrow
PEGS Boston Summit
Not Confirmed

06

Ningxia Labschem Co Ltd

Country
arrow
PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 42012

Submission : 2025-05-26

Status : Active

Type : II

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

read-more
read-moreread-more

01

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

ORFORGLIPRON

NDC Package Code : 73212-106

Start Marketing Date : 2025-01-06

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1g/g)

Marketing Category : BULK INGREDIENT

blank

02

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

ORFORGLIPRON CALCIUM

NDC Package Code : 63419-0603

Start Marketing Date : 2024-12-11

End Marketing Date : 2027-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

03

HOVIONE LIMITED

Portugal
PEGS Boston Summit
Not Confirmed
arrow

HOVIONE LIMITED

Portugal
arrow
PEGS Boston Summit
Not Confirmed

ORFORGLIPRON CALCIUM

NDC Package Code : 51473-1904

Start Marketing Date : 2024-12-11

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (30kg/100kg)

Marketing Category : DRUG FOR FURTHER PROCESSING

blank

04

HOVIONE LIMITED

Portugal
PEGS Boston Summit
Not Confirmed
arrow

HOVIONE LIMITED

Portugal
arrow
PEGS Boston Summit
Not Confirmed

ORFORGLIPRON CALCIUM

NDC Package Code : 51473-1905

Start Marketing Date : 2024-12-11

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (30kg/100kg)

Marketing Category : DRUG FOR FURTHER PROCESSING

blank

05

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

ORFORGLIPRON CALCIUM

NDC Package Code : 50909-1924

Start Marketing Date : 2024-12-11

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (30kg/100kg)

Marketing Category : DRUG FOR FURTHER PROCESSING

blank

06

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

ORFORGLIPRON CALCIUM

NDC Package Code : 50909-1925

Start Marketing Date : 2024-12-11

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (30kg/100kg)

Marketing Category : DRUG FOR FURTHER PROCESSING

blank

07

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

ORFORGLIPRON

NDC Package Code : 24538-601

Start Marketing Date : 2025-12-15

End Marketing Date : 2027-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

08

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

ORFORGLIPRON

NDC Package Code : 24538-600

Start Marketing Date : 2025-12-15

End Marketing Date : 2027-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

09

ETERNAL WEALTH(CHINA)LIMITED

Country
PEGS Boston Summit
Not Confirmed
arrow

ETERNAL WEALTH(CHINA)LIMITED

Country
arrow
PEGS Boston Summit
Not Confirmed

ORFORGLIPRON CALCIUM

NDC Package Code : 85793-004

Start Marketing Date : 2025-08-11

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (100g/100g)

Marketing Category : BULK INGREDIENT

blank

10

ETERNAL WEALTH(CHINA)LIMITED

Country
PEGS Boston Summit
Not Confirmed
arrow

ETERNAL WEALTH(CHINA)LIMITED

Country
arrow
PEGS Boston Summit
Not Confirmed

ORFORGLIPRON

NDC Package Code : 85793-003

Start Marketing Date : 2025-08-11

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (100g/100g)

Marketing Category : BULK INGREDIENT

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothFujian Genohope Biotech is a leading provider of high-potency peptide APIs, offering GMP quality and worldwide delivery.

Flag China
Digital Content Digital Content

Orforglipron

About the Company : Fujian Genohope Biotech Ltd, established in 2019, specializes in high-potency polypeptide APIs and provides global API and preparation manufacturing services. Co-founded by New Hop...

Fujian Genohope Biotech Ltd, established in 2019, specializes in high-potency polypeptide APIs and provides global API and preparation manufacturing services. Co-founded by New Hope Hosencare Brothers and Taiwan Genovior Biotech Corporation, the company operates from the Cross-Strait Biotechnology and Health and Medical Industry Cooperation Zone in Fujian, China. With a 70,000-square-meter GMP-compliant facility and 11 production lines, it meets regulatory requirements for China, the U.S., and international markets. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Company Banner

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

Flag U.S.A
Digital Content Digital Content

Orforglipron

About the Company : Transo-Pharm is a licensed distributor of pharmaceutical components for human and veterinary markets. The company supports the full API life cycle, from development to sales, and a...

Transo-Pharm is a licensed distributor of pharmaceutical components for human and veterinary markets. The company supports the full API life cycle, from development to sales, and acts as a sourcing and regulatory marketing agent for API manufacturers. Transo-Pharm assists with DMF setup, GMP consulting, and regulatory activities, supported by a regulatory team, warehouse facilities, proprietary API process IPs, and laboratory partnerships, with offices in Shanghai, Hong Kong, Singapore, and the US. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Transo Pharm USA Company Banner

03

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothShanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.

Flag China
Digital Content Digital Content

Orforglipron Calcium Hydrate

About the Company : Shanghai Minbiotech is specializing in the R&D and production of advanced pharmaceutical intermediates and biological APIs. There are more than 1000 square meters of R&D centers in...

Shanghai Minbiotech is specializing in the R&D and production of advanced pharmaceutical intermediates and biological APIs. There are more than 1000 square meters of R&D centers in Nantong, Jiangsu and Jinan, Shandong, with more than 13,000㎡ of production sites. While supplying products to customers, the company also provides services such as technology development, technology transfer and technology exchange, aiming to provide customers with comprehensive supply and solutions in the biomedical industry. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Shanghai Minbiotech CB

04

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothHiray Pharma Solutions partners with global innovators to develop, manufacture and commercialize high-quality APIs and intermediates.

Flag China
Digital Content Digital Content

Orforglipron Calcium Hydrate

About the Company : Hiray Pharma Solutions is a global end-to-end CDMO specializing in APIs and intermediates. The company offers integrated services across Process R&D, Analytical R&D, manufacturing,...

Hiray Pharma Solutions is a global end-to-end CDMO specializing in APIs and intermediates. The company offers integrated services across Process R&D, Analytical R&D, manufacturing, and Quality Control, enabling efficient scale-up and commercialization. With strong expertise in chemical synthesis and process optimization, Hiray ensures regulatory compliance, EHS standards, and IP protection while delivering high-quality products on time to pharmaceutical partners worldwide. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Company Banner

05

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Flag India
Digital Content Digital Content

Orforglipron Calcium Hydrate

About the Company : Founded in 1984, DRL is well-known for its generic APIs and its track record in drug product development. It is one of the earliest pharma API manufacturers with a diverse portfoli...

Founded in 1984, DRL is well-known for its generic APIs and its track record in drug product development. It is one of the earliest pharma API manufacturers with a diverse portfolio that provides high-quality, low-cost APIs to leading pharma companies in 80+ countries. It has 8 USFDA-inspected facilities – 6 in India & 1 each in Mexico & the UK & are inspected by international regulatory authorities on a regular basis. Its facilities are supplemented by formulation facilities that provide a wide range of dosage forms. Product(s) under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act and not for commercial sale
Dr Reddy Company Banner

06

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothChina’s top API & intermediate manufacturer, delivering advanced CMO/CDMO solutions to 60+ countries, empowering global health progress

Flag China
Digital Content Digital Content

Orforglipron Calcium Hydrate

About the Company : Shandong Chenghui Shuangda Pharmaceutical Co., Ltd. specializes in API and advanced intermediate R&D and manufacturing, delivering comprehensive CDMO/CRO/OEM services and Finished ...

Shandong Chenghui Shuangda Pharmaceutical Co., Ltd. specializes in API and advanced intermediate R&D and manufacturing, delivering comprehensive CDMO/CRO/OEM services and Finished Formulation Technology Transfer. With 24 years' expertise, our 6 GMP workshops ensure 100-ton monthly cGMP-compliant capacity. We hold 21 NMPA-registered APIs, 4 US-DMF filings, 8 CEP applications, and passed US FDA, Korea MFDS, and global client audits. Note: Patent-protected products are for R&D use only per Patent Act, not for commercial sale.
Shandong Chenghui Shuangda Pharmaceutical

07

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothComhony Biotech manufactures fermentation & semi-synthetic APIs which aim at dermatology, anti-biotics; mitochondria & memory health.

Flag China
Digital Content Digital Content

Orforglipron

About the Company : Comhony Biotech supplies APIs and nutraceutical ingredients to pharmaceutical and nutraceutical clients worldwide. Using proprietary technologies, the company manufactures fermenta...

Comhony Biotech supplies APIs and nutraceutical ingredients to pharmaceutical and nutraceutical clients worldwide. Using proprietary technologies, the company manufactures fermentation and semi-synthetic products for dermatology and antibiotics (APIs), as well as mitochondria and memory health (nutraceuticals). Comhony’s manufacturing facility is approved by the NMPA (CFDA) and complies with Chinese GMP standards, equivalent to EU, WHO, and ICH/Q7 GMP requirements. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Comhony company banner

08

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothLupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

Flag India
Digital Content Digital Content

Orforglipron

About the Company : Lupin Manufacturing Solutions (LMS), a wholly owned Lupin subsidiary, offers high-quality APIs and end-to-end CDMO services from R&D to commercial scale. Backed by five decades of ...

Lupin Manufacturing Solutions (LMS), a wholly owned Lupin subsidiary, offers high-quality APIs and end-to-end CDMO services from R&D to commercial scale. Backed by five decades of pharma expertise, LMS combines cost efficiency with regulatory excellence. With world-class sites in Dabhasa and Vizag, and an R&D center in Pune, we deliver integrated, sustainable, and globally compliant solutions that accelerate drug development and reduce environmental impact. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Company Banner

09

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Orforglipron Calcium Hydrate

About the Company : Jingke Biotechnology is a technology-driven biotechnology company focused on advancing life science research and molecular diagnostics through innovative sample preparation and nuc...

Jingke Biotechnology is a technology-driven biotechnology company focused on advancing life science research and molecular diagnostics through innovative sample preparation and nucleic acid extraction solutions. With expertise in magnetic bead technology and molecular biology, the company develops high-quality products that support research, clinical, and diagnostic laboratories worldwide. Committed to innovation, quality, and scientific excellence, Jingke Biotechnology delivers reliable solutions that enable accurate, efficient, and reproducible results.
blank

10

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Orforglipron Calcium Hydrate

About the Company : Rui Laboratories was established in the year 2017, as a medium scale industry with limited products. We dedicate ourselves to manufacturing of Pharma Intermediates and APIs meeting...

Rui Laboratories was established in the year 2017, as a medium scale industry with limited products. We dedicate ourselves to manufacturing of Pharma Intermediates and APIs meeting the quality standards of National and International customers and committed to work under safe and healthy environment.Rui Laboratories has great respect for knowledge and encourages the talented work force in its organization. Talented employees are in good positions and contributing in a remarkable way to achieve the goals of the organization. All those joining our Rui family are taught on morals and ethics
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

STOCK RECAP #PipelineProspector

read-more
read-more

WEEKLY NEWS RECAP #Phispers

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Looking for 2212020-52-3 / Orforglipron Calcium Hydrate API manufacturers, exporters & distributors?

Orforglipron Calcium Hydrate manufacturers, exporters & distributors 1

79

PharmaCompass offers a list of Orforglipron Calcium Hydrate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Orforglipron Calcium Hydrate manufacturer or Orforglipron Calcium Hydrate supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Orforglipron Calcium Hydrate manufacturer or Orforglipron Calcium Hydrate supplier.

API | Excipient name

Orforglipron Calcium Hydrate

Synonyms

2212020-52-3, Ly3502970, Chembl4446782, Ly-3502970, 3-[(1s,2s)-1-[5-[(4s)-2,2-dimethyloxan-4-yl]-2-[(4s)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4h-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methylcyclopropyl]-4h-1,2,4-oxadiazol-5-one, 3-[(1s,2s)-1-(5-[(4s)-2,2-dimethyloxan-4-yl]-2-{(4s)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1h-indazol-5-yl)-2-oxo-2,3-dihydro-1h-imidazol-1-yl]-4-methyl-2,4,6,7-tetrahydro-5h-pyrazolo[4,3-c]pyridine-5-carbonyl}-1h-indol-1-yl)-2-methylcyclopropyl]-1,2,4-oxadiazol-5(4h)-one

Cas Number

2212020-52-3

Unique Ingredient Identifier (UNII)

7ZW40D021M

Orforglipron Manufacturers

A Orforglipron manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Orforglipron, including repackagers and relabelers. The FDA regulates Orforglipron manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Orforglipron API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Orforglipron manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.

Orforglipron Suppliers

A Orforglipron supplier is an individual or a company that provides Orforglipron active pharmaceutical ingredient (API) or Orforglipron finished formulations upon request. The Orforglipron suppliers may include Orforglipron API manufacturers, exporters, distributors and traders.

click here to find a list of Orforglipron suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.

Orforglipron USDMF

A Orforglipron DMF (Drug Master File) is a document detailing the whole manufacturing process of Orforglipron active pharmaceutical ingredient (API) in detail. Different forms of Orforglipron DMFs exist exist since differing nations have different regulations, such as Orforglipron USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Orforglipron DMF submitted to regulatory agencies in the US is known as a USDMF. Orforglipron USDMF includes data on Orforglipron's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Orforglipron USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Orforglipron suppliers with USDMF on PharmaCompass.

Orforglipron NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Orforglipron as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Orforglipron API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Orforglipron as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Orforglipron and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Orforglipron NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Orforglipron suppliers with NDC on PharmaCompass.

Orforglipron GMP

Orforglipron Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Orforglipron GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Orforglipron GMP manufacturer or Orforglipron GMP API supplier for your needs.

Orforglipron CoA

A Orforglipron CoA (Certificate of Analysis) is a formal document that attests to Orforglipron's compliance with Orforglipron specifications and serves as a tool for batch-level quality control.

Orforglipron CoA mostly includes findings from lab analyses of a specific batch. For each Orforglipron CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Orforglipron may be tested according to a variety of international standards, such as European Pharmacopoeia (Orforglipron EP), Orforglipron JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Orforglipron USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty